Experiment Protocol Biomedical Engineer in Spain Barcelona –Free Word Template Download with AI

This Experiment Protocol outlines the methodology for testing a new subcutaneous biosensor designed for continuous glucose monitoring (CGM). The research is conducted under the supervision of a qualified Biomedical Engineer within the regulatory framework of Spain, specifically adhering to the standards set by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the European Union Medical Device Regulation (EU MDR 2017/745).

Barcelona serves as the primary site for this investigation due to its advanced healthcare infrastructure and the presence of leading biomedical research institutions. The Biomedical Engineer leading this project is responsible for ensuring that the device design, testing procedures, and data analysis meet both scientific rigor and legal compliance.

The primary objective of this experiment is to validate the accuracy, reliability, and safety of the proposed biosensor prototype when used in a controlled clinical environment in Barcelona.

Secondary objectives include:

• Assessing the biocompatibility of the sensor material over a 72-hour period.
• Evaluating the signal-to-noise ratio in real-world physiological conditions.
• Ensuring compliance with ISO 13485 quality management standards relevant to medical devices.

All procedures described in this Experiment Protocol have been reviewed and approved by the Clinical Research Ethics Committee (CEIC) of the participating hospital in Barcelona. The study adheres to the Declaration of Helsinki and the General Data Protection Regulation (GDPR) regarding the handling of personal health data.

The Biomedical Engineer must ensure that all equipment used is calibrated and certified according to Spanish national standards. Any adverse events must be reported immediately to the AEMPS and the local ethics committee.

4.1 Study Design
This is a prospective, single-arm, observational study involving 20 adult participants with Type 2 diabetes. Participants will be recruited from a specialized endocrinology clinic in Barcelona.

4.2 Device Description
The device under investigation is a minimally invasive electrochemical biosensor. The Biomedical Engineer has designed the sensor to utilize a novel enzyme layer that enhances glucose detection sensitivity. The device transmits data wirelessly to a handheld receiver.

4.3 Procedure
Upon obtaining informed consent, the Biomedical Engineer or a trained technician will insert the sensor into the subcutaneous tissue of the participant's abdomen. The insertion process will follow strict aseptic techniques.

Data collection will occur continuously over 72 hours. Participants will perform capillary blood glucose tests using a standard glucometer at four specific times daily to serve as reference values. The Biomedical Engineer will analyze the correlation between the sensor readings and the reference values.

All data will be stored on secure servers located within the European Union to comply with GDPR. The Biomedical Engineer will use statistical software to calculate the Mean Absolute Relative Difference (MARD) between the sensor readings and the reference blood glucose values.

Data integrity is paramount. The protocol requires daily backups and audit trails to track any modifications to the dataset. Only authorized personnel involved in the study in Barcelona will have access to the raw data.

Potential risks associated with this experiment include minor skin irritation, infection at the insertion site, and inaccurate glucose readings. The Biomedical Engineer has implemented a risk management plan in accordance with ISO 14971.

Participants will be instructed to remove the sensor immediately if they experience severe pain, swelling, or signs of infection. A local physician in Barcelona will be on call to address any medical emergencies arising from the device usage.

This Experiment Protocol provides a comprehensive framework for the evaluation of the new biosensor technology. By adhering to these guidelines, the Biomedical Engineer and the research team in Barcelona aim to contribute valuable data to the field of biomedical engineering, potentially improving diabetes management tools for patients across Spain and Europe.